Heather J. Litman

Thermo Fisher Scientific (United States) — United States

Medicine · Health Sciences

37h-index5.5kcitations148works3.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Pelvic floor disorders treatments(54), Rheumatoid Arthritis Research and Therapies(32), Urinary Bladder and Prostate Research(31), Anorectal Disease Treatments and Outcomes(25), Urinary Tract Infections Management(12)

Publications148 total

Features Associated with Therapy Switch Among PPD CorEvitas Psoriasis Registry Patients
Dermatology and Therapy·2026Open Access
Development and External Validation of a Multivariable Predictive Model for Progression to Difficult‐to‐Treat Rheumatoid Arthritis in Biologic‐Experienced Patients
Arthritis Care & Research·2025· 2 citedOpen Access
Pragmatic Policy Development via Interpretable Behavior Cloning
arXiv (Cornell University)·2025Open Access
Applying Bias Correction Methods to Build Hybrid Controls Using Real‐World Patients for a Phase <scp>IIb</scp> Randomized Controlled Trial of Baricitinib for Rheumatoid Arthritis
Pharmaceutical Statistics·2025Open Access
POS0648 DEVELOPMENT AND EXTERNAL VALIDATION OF A PREDICTIVE MODEL FOR PROGRESSION TO DIFFICULT-TO-TREAT RHEUMATOID ARTHRITIS IN BIOLOGIC-EXPERIENCED PATIENTS
Annals of the Rheumatic Diseases·2025Open Access
How Should We Represent History in Interpretable Models of Clinical Policies?
arXiv (Cornell University)·2024Open Access
Disease activity of rheumatoid arthritis and kidney function decline: a large prospective registry study
Annals of the Rheumatic Diseases·2024· 24 citedOpen Access
Assessing clusters of comorbidities in rheumatoid arthritis: a machine learning approach
Arthritis Research & Therapy·2023· 10 citedOpen Access
Patterns in the Sequential Treatment of Patients With Rheumatoid Arthritis Starting a Biologic or Targeted Synthetic <scp>Disease‐Modifying</scp> Antirheumatic Drug: <scp>10‐Year</scp> Experience From a <scp>US‐Based</scp> Registry
ACR Open Rheumatology·2023· 9 citedOpen Access
Patterns in the sequential treatment of rheumatoid arthritis patients starting a b/tsDMARD: 10-year experience from a US-based registry
2023· 2 citedOpen Access
Fracture in clinical studies of tofacitinib in rheumatoid arthritis
Therapeutic Advances in Musculoskeletal Disease·2022· 14 citedOpen Access
Assessing the change in disease severity based on depressive symptoms in real-world psoriasis patients
Journal of Comparative Effectiveness Research·2021
Postapproval Comparative Safety Study of Tofacitinib and Biological Disease‐Modifying Antirheumatic Drugs: 5‐Year Results from a United States–Based Rheumatoid Arthritis Registry
ACR Open Rheumatology·2021· 135 citedOpen Access
Characteristics of Patients with Psoriasis Treated with Apremilast in the Corrona Psoriasis Registry
Dermatology and Therapy·2021· 5 citedOpen Access
15457 Secukinumab significantly improves clinical and patient-reported outcomes up to 18 months of follow-up: Real-world evidence from a US psoriasis registry
Journal of the American Academy of Dermatology·2020
13807 Characterization of nonresponders to interleukin-17 inhibitors in moderate to severe psoriasis patients enrolled in the Corrona Psoriasis Registry
Journal of the American Academy of Dermatology·2020
Real-World Evidence to Contextualize Clinical Trial Results and Inform Regulatory Decisions: Tofacitinib Modified-Release Once-Daily vs Immediate-Release Twice-Daily for Rheumatoid Arthritis
Advances in Therapy·2020· 14 citedOpen Access
Persistence on biologic DMARD monotherapy after achieving rheumatoid arthritis disease control on combination therapy: retrospective analysis of corrona registry data
Rheumatology International·2020· 10 citedOpen Access
Characterization of real-world psoriasis patients with and without a history of depression: The Corrona Psoriasis Registry
Journal of the American Academy of Dermatology·2020· 2 citedOpen Access
Assessing disease severity in bio-naïve patients with RA on treatment with csDMARDs: insights from the Corrona Registry
Clinical Rheumatology·2019· 5 citedOpen Access
page 1 of 8Next →

Frequent Co-authors

Larry Sirls(15), Stephen R. Kraus(15), Holly E. Richter(13), Gary E. Lemack(13), Peggy Norton(11), Toby C. Chai(11), Charles W. Nager(11), John B. McKinlay(11), Sharon L. Tennstedt(10), Halina M. Zyczynski(9), Carol L. Link(9), Kimberly Kenton(8), John W. Kusek(8), Michael Albo(6), Kimberly J. Dandreo(6), Linda Brubaker(6), Philippe E. Zimmern(6), Elizabeth R. Mueller(5), Mary P. FitzGerald(5), Anne M. Stoddard(4)